Business Context and Reporting Period
This Form 8-K Current Report was filed by MaxLinear, Inc. on September 9, 2020. The report details the closing of the company's acquisition of NanoSemi, Inc. ("NanoSemi").
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial disclosure relates to the equity consideration for the acquisition:
- Equity Issuance: 804,163 shares of MaxLinear common stock were issued to former NanoSemi stockholders.
- Transaction Type: Partial consideration for the acquisition of NanoSemi.
Material Changes
The material change reported is the completion of the acquisition of NanoSemi, Inc. on September 9, 2020. This transaction resulted in the issuance of unregistered equity securities to the former shareholders of the acquired entity.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure of the transaction. Key details regarding the transaction include:
- Regulatory Basis: The share issuance relied on exemptions under Section 4(a)(2) of the Securities Act or Regulation D.
- Registration Rights: MaxLinear has agreed to provide certain registration rights to the former NanoSemi stockholders regarding the issued shares.
- Public Disclosure: A press release announcing the acquisition was issued on the same date and is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the total consideration paid for NanoSemi, Inc., as this filing only discloses the equity portion (804,163 shares).
- Review the attached press release (Exhibit 99.1) for strategic rationale and potential financial impact.
- Confirm the terms of the registration rights agreement granted to former NanoSemi stockholders.
- Check subsequent filings for the impact of this acquisition on MaxLinear's consolidated financial statements.